Equal purity testing for ranitidine Form 1 and Form 2 are appropriate, judge says.
This article was originally published in The Tan Sheet
Executive Summary
GLAXO CALL FOR HIGHER TECHNOLOGY TO PROVE RANITIDINE FORM 2 PURITY REJECTED by federal court Judge Terrence Boyle in a July 5 ruling. Glaxo Wellcome cannot demand that Novopharm use more advanced technology to prove the purity of its Form 1 ranitidine product than that used in Glaxo's original ranitidine patent, the judge stated.